Merck HIV Drug Strategy Seen Shielding Patent: Corporate India

Merck & Co. is set to sell an HIV medication in India by mid-year in partnership with local company Cipla Ltd., a strategy that may help the U.S. drugmaker protect its patent as the Asian nation seeks cheaper generics.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.